Heinz-Josef Lenz, MD, FACP, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer.
Heinz-Josef Lenz, MD, FACP, professor of medicine, J. Terrance Lanni Chair in Gastrointestinal Cancer Research, and co-director, University of Southern California (USC) Center for Molecular Pathway and Drug Discovery, at the USC Norris Comprehensive Cancer Center, discusses updated results from the phase II CheckMate-142 trial in metastatic colorectal cancer (mCRC).
The trial examined frontline nivolumab (Opdivo) plus low-dose ipilimumab (Yervoy) in treatment-naïve patients with microsatellite instability-high/mismatch repair deficient mCRC.
At a median follow-up of 25.4 months, the objective response rate was 58%. Moreover, progression-free survival (PFS) was not yet reached with the combination.
These data suggest that the combination can provide patients with durable benefit,says Lenz.